The WHO Tobacco Product Regulation Study Group (TobReg) has proposed three regulatory models for cigarettes, each creating mandatory limits for emissions of nine smoke toxicants. One approach proposes country-specific limits, using median or 1.25Â median toxicant/nicotine emission ratios. A second model provides fixed toxicant-ratio limits. The third model limits were three times the lowest toxicant emission on a market. Currently, the practical implications of these models are largely unknown.
Introduction
The mortality and morbidity associated with cigarette use is a hazard currently facing over a billion smokers (WHO, 2016a) . Health risks have been found to diminish after cessation and disease progression may slow substantially (US Department of Health and Human Services, 2014). However, despite significant global Public Health efforts towards smoking cessation, WHO projections suggest that if current trends continue annual deaths from smoking are likely to increase by 2030 (WHO, 2011) .
Since the 1950s scientists have sought to explain the risks associated with cigarette smoking by identifying and quantifying compounds in tobacco and smoke that have toxic properties. These compounds are often referred to as toxicants and several of them have been identified, the number of which has grown longer as toxicological understanding and analytical techniques have improved. The current reference point for cigarette smoke toxicants is the established list of over 90 Harmful or Potentially Harmful Compounds (HPHC) identified by a Technical Advisory group to the FDA in 2011 (FDA, 2012) .
The US Institute of Medicine has expressed the view that some of the harm caused by tobacco use may potentially be reduced through introduction of products that might result in substantial reduction in exposure to one or more tobacco toxicants (Stratton et al., 2001) .
Cigarette smoke toxicants have been the focus of increased regulatory interest since this time (Liu et al., 2011) . Traditional approaches for the regulation of cigarette products, based upon reporting and limiting cigarette emissions of tar, nicotine and carbon monoxide measured under the ISO smoking regime have been replaced or supplemented by reporting requirements on cigarette smoke toxicants and at additional smoking regimes. Starting with the mandated measurement and reporting of toxicant emissions in Canada (Health Canada, 2000) and Brazil (ANVISA, 2007) , the requirement to measure and report emissions has gradually spread to other countries such as Taiwan (Taiwan, 2010) , and the USA (FDA, 2012) . Cigarette emission regulations currently show a great deal of inconsistency from country to country, ranging from ceilings on tar, nicotine and carbon monoxide in the European Union and other jurisdictions to detailed, but differing, requirements for annual perproduct emission reporting of 7 constituents in Taiwan, 18 constituents in the USA, and more than 40 in Brazil, Canada and Venezuela (Liu et al., 2011) .
In 2003 the World Health Organization (WHO) adopted the Framework Convention on Tobacco Control (FCTC), to which 168 countries globally are signatories and 180 are parties (WHO, 2016b) . The FCTC has an objective of "providing a framework for tobacco control measures to be implemented by the Parties at the national, regional and international levels in order to reduce continually and substantially the prevalence of tobacco use and exposure to tobacco smoke". FCTC represents a mechanism for global deployment of tobacco control initiatives (WHO, 2005) .
Articles 9 and 10 of the FCTC focus on tobacco product regulation (WHO, 2005) . As a step towards this, in 2008, a WHO advisory group on Tobacco Product Regulation (TobReg) published a new strategy for tobacco product regulation (WHO, 2008; Burns et al., 2008) . The proposed strategy focused on use of standardised measures of cigarette smoke toxicity that characterised, as far as possible, potential differences in harm caused by different cigarettes. Central to TobReg's strategy is the mandated lowering of nine separate toxicants in cigarette smoke emissions. The toxicants identified for mandated reduction were chosen based on toxicity, observations of differences in yields across brands, availability of technology or other approaches to reduce yields, and the existence of markets for low yield products. The proposed approach was therefore viewed as an example of the precautionary principle often deployed in public health with parallels drawn to strategies used with other consumer products, where the focus is also to reduce levels of known toxicants present in the product.
The nine selected toxicants: 1,3-butadiene, acetaldehyde, acrolein, benzene, benzo [a] pyrene (B[a]P), carbon monoxide, formaldehyde, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and N'-nitrosonornicotine (NNN), represent a range of chemical classes found in cigarette smoke, covering both the vapour phase and the particulate phase, and were viewed as implicated in carcinogenicity, cardiovascular and pulmonary toxicity; they also commonly appear in various other existing lists of identified smoke toxicants. As TobReg's proposals were founded upon the widely accepted regulatory practice of reducing toxicants in products intended for human use TobReg did not regard it as necessary to have specific proof of a link between a lower level of these toxicants in cigarette smoke and a lower level of human disease. This is an important point, as links between individual cigarette smoke toxicants and human disease are currently incomplete (Burns et al., 2008) .
The 2008 TobReg proposals recommended two models, both of which established emission limits for each of the 9 toxicants, as measured using the Health Canada Intense smoking regime, and expressed per milligram of nicotine. Use of the ratio to nicotine was proposed on the basis that machine-measured per-cigarette smoke emissions were unreliable estimates of smoker's exposure to cigarette smoke. TobReg noted that individual smokers "seek to achieve nicotine intakes sufficient to satisfy their addiction". Use of a toxicant/nicotine ratio was therefore described as shifting focus away from quantity of smoke generated per cigarette and preventing interpretation that the values obtained represent a measure of smoker exposure to toxicants (WHO, 2008) .
Under the TobReg proposals failure of a cigarette brand to meet each of the nine separate limits would lead to its withdrawal from sale on a market. The strategy was recommended to be implemented in phases, starting with annual reporting of toxicant levels for 2e3 years, setting toxicant limits from these data, enforcing limits two years after they are set, and potentially lowering limits progressively over time. The aim in setting the limits was to balance the need to regulate a range of toxicants, to mandate lowering those toxicants to the greatest extent and yet not to eliminate most brands from the market in their current form (WHO, 2008) .
Under the first TobReg model ("model 1") the toxicant emission limits for a country were to be set by measuring emission ratios to nicotine for all products on a market, calculating the median value for each toxicant, setting this value as the limit for NNN and NNK, and setting the limits for the other seven toxicants as 125% of their respective median values (Burns et al., 2008) . The second TobReg model ("model 2") was proposed for countries possessing limited laboratory capacity. This model provided two sets of fixed regulatory limits that could be deployed across multiple countries. One set of limits, labelled 'international brands', was calculated from an International measurement survey of 49 Philip Morris cigarette brands, conducted in 2001 (Counts et al., 2005) , and were proposed for use in countries whose cigarette products were predominately US-or American blend products, or where the style of cigarettes on the market are not readily identifiable. The second set of limits, labelled 'Canadian brands', were calculated from a set of 91 Canadian brands reported to Health Canada in 2004, reduced to exclude brands with levels of NNN per mg nicotine >0.1 ng, which eliminates most US and Gauloise brands (12 brands), and duplicate and erroneous values (31 brands), leaving a database of 48 Canadian products representing "unblended cigarettes containing predominantly flue-cured (bright) tobacco"; these limits were intended for use in countries whose cigarette products reflected more flue-cured or "Virginia" blend style products (WHO, 2008) .
TobReg conducted a limited impact assessment of the proposed models using these datasets, and concluded that regulation of brands for toxicants other than NNK and NNN would result in 40e41% of brands failing to meet the set of limits without modification (WHO, 2008) . This form of analysis was based on the belief that there is existing technology for dramatically lowering the nitrosamine contents of tobaccos. This position arose from analysis showing wide differences in nitrosamine emissions between brands and geographic sources, and reports that modifying North American flue-curing approaches from direct-heating to indirect heating mechanisms were lowering nitrosamine levels in USA and Canada tobaccos and cigarettes (IARC, 2004; Gray and Boyle, 2004 (WHO, 2015) . The technical report includes an independent commentary by the late Dr Nigel Gray which, whilst not necessarily representing the view of the WHO or TobReg, was unanimously recommended for inclusion in the report due to 'the thought-provoking nature of its content and goals'. Gray set forth a third model ("model 3") of toxicant emission limits based on a 'generous' upper limit set at three times the lowest toxicant emission level achieved on the market, reviewable after 2 years and then, where practical, set lower.
A limitation in the TobReg approach, identified by TobReg (WHO 2008) , was the lack of available full-market data with which to assess the impact of TobRegs proposals and consequent reliance on the relatively small dataset of publically available toxicant emission values. TobReg noted the limitations involved in the limited dataset covering few geographic sources and cigarette brands, and recognised that the performance of charcoal filter cigarettes were not well characterised by the approach of normalising yields to nicotine (a limitation that might also apply to products with different circumferences). In the eight years following publication of the TobReg proposals the limited database of cigarette toxicant yields has not grown significantly, and therefore the impact of TobRegs proposed toxicant-reduction regulations on real world cigarette markets, together with the practical realities of adhering to the proposals, have not been tested and their implications remain unclear.
The aim of the present study was to fill this knowledge-gap, and thereby assess the real-world impact of TobReg's proposals. Four diverse cigarette markets, identified initially by principal component analysis (PCA) of an extensive database of smoke emission values (Camacho et al., 2015) , were chosen to understand the performance of the TobReg proposals under the widest possible range of testable conditions. Cigarette products were sampled from these countries following the TobReg approach, and smoke emissions of the nine toxicants and nicotine were determined for these products under the Health Canada intense (HCI) smoking regime. These data were then used to test the three TobReg models, in order to characterise their impact on these four diverse cigarette markets.
Methods

Selection of study markets
PCA was used to select four diverse markets with which to assess the impact of the TobReg proposals for mandated lowering of emissions of nine smoke toxicants. An in-house database containing recent (2006e2011) measurements on tobacco filler blend components, mainstream smoke toxicant emissions, and various physical parameters for 811 commercial cigarette products from 79 markets was used in the PCA to identify four markets with distinctly different product styles.
Smoke toxicant emission yields were not used as variables in the PCA because the majority of the in-house data had been generated under the ISO smoking regime, rather than HCI regime upon which the TobReg recommendations are based (WHO, 2008; Burns et al., 2008) . Instead, the cigarette filler blend components NNK and NNN, which are direct precursors of NNK and NNN in smoke, were used, together with total sugar, a precursor of the smoke toxicant formaldehyde. A fourth variable, filter charcoal loading was included in the PCA due to its ability to affect the levels of volatile smoke toxicants, such as acetaldehyde, acrolein, benzene and 1,3-butadiene. The variables entered in the PCA include factors affecting eight of the nine toxicants proposed for mandated lowering, carbon monoxide (CO) being the exception. The PCA was conducted via JMP Pro version 10 (SAS Institute, Cary, NC, USA).
Study products
After the study markets had been selected by PCA, a list of all current cigarette products (regardless of manufacturer) on sale in each of those markets was obtained by local BAT sales-force employees or in the case of Brazil, where product registration is a regulatory requirement, the product list was obtained from ANVISA. The Brazilian market was sampled in Q1 2012; Romania in Q4 2012; Australia in Q1 2013; and Germany in Q4 2013. The products were either sourced directly from BAT factories or purchased from the market place in the case of brands from other manufacturers. The acquisition of products took several months for each market. Once acquired product samples were sent directly to the analysis laboratory.
Product analysis
All products were analysed at a single, ISO 17025 accredited laboratory in Brazil. The four markets were analysed sequentially in a series of batches wherein each market was measured as a whole prior to commencement of the next study market. This process lasted more than 2 years, owing to the large number of study products.
Smoke toxicant emissions of acetaldehyde, acrolein, 1,3-butadiene, benzo[a]pyrene (B[a]P), benzene, CO, formaldehyde, NNN, NNK, tar, and nicotine were determined under the HCI regime. If the product contained a flavour capsule then analysis was carried out after the capsule had been crushed. Five replicate measurements were conducted per product for acetaldehyde, acrolein, 1,3-butadiene, B[a]P, benzene, formaldehyde, NNN and NNK, whereas eight replicates were conducted for tar, nicotine and CO, in compliance with ISO sampling requirements for these toxicants (ISO 8243:2013) .
The mainstream smoke toxicants were analysed by standard methods that have been internally validated for repeatability and reproducibility (AOAC 2013; ISO 1994) . The methods follow, or are based on, internationally standardised or recognised protocols (i.e. ISO, CORESTA or official Health Canada methods). The methods are multi-analyte, whereby members of a group of toxicants (e.g. volatiles or carbonyls or tobacco specific nitrosamines, etc.) are analysed simultaneously from the same cigarettes. Details of the analytical methods are given in the Supplementary Information.
Data analysis
Smoke emissions data were collated and toxicant-to-nicotine emission ratios were calculated using Base SAS version 9.3 (SAS Institute). Product assessment against potential toxicant emission ratio limits was performed with Microsoft Excel 2010 (Microsoft Corporation, Redmond, WA, USA). The four markets were analysed separately.
In analysing TobReg model 1, for each market, the limit for each of the nine toxicants was calculated in accordance with TobReg (WHO, 2008) as follows. For each toxicant, the mean yields of toxicant and nicotine for each product were used to calculate the mean emission level as a ratio to the mean yield of nicotine: the emission ratio value. The median emission ratio value per market was then determined across the range of toxicant ratios for all products measured in that market. The toxicant emission limits for each market were determined as the median emission ratio value for NNN and NNK, and 125% of the median emission ratio value for formaldehyde, acetaldehyde, acrolein, B[a]P, CO, 1,3-butadiene and benzene. With TobReg model 2, the limits used were those published by TobReg (WHO, 2008 , Burns et al., 2008 . With TobReg model 3 (WHO, 2015) the limits were calculated for each market by establishing the minimum per-cigarette emission level for each toxicant, and multiplying this value by three. The measured toxicant emission ratio values, or toxicant emission levels, were compared to the limits for each model, and the number of compliant and non-compliant products calculated with regard to each toxicant limit individually and also when all nine limits were applied simultaneously.
Results
3.1. Selection of study markets using principal component analysis PCA was used to identify four markets with diverse products. The four input variables, filler blend content of NNN, NNK and total sugar, and filter charcoal loading (Supplementary Table 1 ), were chosen on the basis of data measured by BAT on 811 products from 79 countries (Supplementary Table 2 ). The PCA used parameters representing the majority of the nine TobReg toxicants. B[a]P in filler blend was also considered as a variable for the PCA, as it is a driver for B[a]P smoke emissions, however this data was not available for all products in the in-house database. Other physical measures, such as circumference, were not included in the PCA as the majority of in-house data was from king-size circumference cigarettes.
The PCA defined a variable for blend character (i.e., TSNA to formaldehyde (sugar)) as principal component 1 (PC1), accounting for~45% of the variation in product measurements, and a variable for the amount of charcoal included in the cigarette filter as principal component 2 (PC2), accounting for~26% of the variation associated within these measurements. The PC1 and PC2 scores of the products were plotted to identify diverse markets (Fig. 1) .
From the score plot, we identified four groupings that described the most diverse market scenarios within our database. These four markets were Brazil (mixed blend products, low filter charcoal prevalence; Fig After selection of the four study markets, current products on sale in each market were obtained for analysis. Sourcing the test products in each market proved logistically very challenging, for reasons such as delisting of product and geographical limitations in distribution. In addition, it was not possible to source a sufficient volume of some products (a minimum of 400 cigarettes per product were required for analysis, with 800 preferred) due to the limited availability of low-market share cigarette brands and product delisting during the sampling exercise. Across the four markets, the percentage of products collected in sufficient quantity for testing was 80% (132 out of 166 products) in Brazil, 93% (138 out of 148 products) in Romania, 97% (172 out of 177 products) in Australia, and 92% (339 out of 367 products) in Germany. Given the difficulty encountered with the sampling exercise, multiple time-point sampling of the type recommended by TobReg was not possible. Nevertheless, the products sampled in this single point-in-time exercise were considered sufficient for the analysis to be conducted as planned.
Mainstream smoke toxicant emissions
HCI mainstream smoke emissions of the nine TobReg toxicants plus nicotine and tar were measured for each test product, and the distribution of toxicant emission yields per market, both on a per cigarette basis and as a ratio to nicotine emission yield, were summarized (Table 1) .
Regarding the toxicant yields per cigarette, fairly normal distributions were observed with mean and median values being similar in each case, and no markedly different values comparing the minimum yield to the lower quartile nor maximum yield to the upper quartile, (Table 1, Supplementary Fig. 1 ). In general, standard deviation measurements were~20% of mean or median values however standard deviations were a larger percentage of the mean or median values for NNN and NNK, particularly for NNN in Australia and NNK in Brazil.
There were a few exceptions due to the inclusion of atypical products. In the Australian market, zero yields of nicotine (and TSNA) were determined for two herbal cigarettes; as a result, these two products were excluded from the yield determinations per mg of nicotine, although their yields of the seven non-TSNA toxicants from these non-tobacco cigarettes were similar to those in conventional cigarettes. The Australian market survey also included a kretek-style product (a blend of tobacco, cloves, and other flavours), which was responsible for the notably high maximum yields of nicotine (3.58 mg/cig), tar (61.5 mg/cig), B[a]P (40.9 ng/cig), formaldehyde (253 mg/cig), acrolein (187 mg/cig) and benzene (135 mg/ cig) in that market. The German market included a cigarette wrapped in a reconstituted tobacco sheet instead of cigarette paper, which produced the notably high maximum yields determined for acetaldehyde (2567 mg/cig), 1,3-butadiene (385mg/cig), benzene (262mg/cig) and CO (72.1 mg/cig) in that market.
Comparing the emissions of each toxicant among the four sampled markets, the Australian market exhibited lower TSNA yields and higher formaldehyde yields, which is consistent with the predominantly flue-cured characteristics of products in this market. B[a]P yields were lower in the Romanian market, whereas nicotine and 1,3-butadiene yields were lower in the Brazilian market (Table 1) .
Considering toxicant yields per mg nicotine (Table 1 , Supplementary Fig. 2 ), summary statistics for yields per mg nicotine were lower as compared with the results per cigarette because, on average, nicotine yields were greater than 1 mg/cig. The exception to this, besides the two herbal Australian products already mentioned, was a locally produced Brazilian product that had the highest levels of NNN (392 ng/cig) and NNK yields (670 ng/ cig) on a per cigarette basis, in that market, and the lowest nicotine yield (0.82 mg/cig) of all the Brazilian products surveyed, and therefore produced notably high TSNA yields per mg nicotine (NNN 479 ng/mg nicotine, NNK 818 ng/mg nicotine). This product also produced the maximum yield ratios in Brazil for B Market-specific toxicant limits were calculated by using the method proposed by TobReg (Table 2 ). The toxicants with the widest range of TobReg limits were the two TSNAs (NNK, 21e78 ng/ mg nicotine; NNN, 27e90 ng/mg nicotine), where the range of limits (difference between highest and lowest limit expressed as a % of the lowest limit) was 230e270%. In contrast, six of the other seven toxicants showed much smaller ranges, an order of magnitude lower, at 17e30%; the range of limits for B[a]P was also comparatively low, at around 50%. Brazil had the highest limits for seven of the nine toxicants with only the 1,3-butadiene limit being relatively low (second lowest when compared across the 6 datasets). Romanian products were notable for having the lowest calculated limits for six toxicants. The lowest TSNA limits were found with Australian products under model 1.
Model 2
Comparing the limits calculated under model 1 with the fixed limits provided by TobReg under model 2 ( Table 2 ), showed that the 'Canadian brands' limits set by TobReg were lower than those calculated in the current study for five of the nine toxicants, but higher for formaldehyde.
Comparing the limits for the two flue-cured datasets (Australia in this study, model 1 vs Canadian brands limits set by TobReg, model 2), the largest discrepancy was in NNK limits, where the Canadian brands limit set by TobReg was more than twice the market-limit determined for Australia in this work; the difference between the limits for the other toxicants ranged from À27% to 20%. For the two US-blended datasets (Germany in this study, model 1 vs International brands limits set by TobReg, model 2), the largest discrepancy was in TSNA limits, where the International brands limits for both NNK and NNN were more than 50% higher than those determined with German brands in this work; otherwise, the differences ranged between À6% and 23% per toxicant. The International brands limit (model 2) for NNN was higher than any of the four markets surveyed in the present study, model 1.
Model 3
Market-specific limits were also calculated according to model 3 (Table 3 ). The toxicants with the widest ranges of limits were again the two TSNAs, with a 170% range of limits for NNK, and a 270% range of limits for NNN. These ranges of TSNA limits with model 3 are similar to the range of limits found with TobReg model 1. The range of model 3 limits for the other seven toxicants are 36e96%, which is a greater range than found under model 1.
Product compliance with limits
Model 1 -market-specific limits
For each market, the proportions of non-compliant products were determined individually for each toxicant (Fig. 3A) and cumulatively when applying all nine toxicant limits simultaneously (Fig. 3B) . Notably, between 72% and 79% of products within each market would be non-compliant following the TobReg model 1 approach (Table 4) , i.e. after the application of all nine marketspecific toxicant limits (WHO, 2008) . The proportions of noncompliant product were also determined cumulatively when applying to both TSNAs (median limits) and cumulatively for the non-TSNA toxicants (125% of median limits), (Fig. 3B) . The consistency of the proportions of non-compliant product across the four markets for each comparison in Fig. 3 emphasises the mathematical nature of this approach.
The main driver of non-compliance in all markets were the limits for the two TSNAs, where, by definition, the TobReg proposed use of median values ensures that 50% of products would be immediately non-compliant with limits for both NNN and NNK. Imperfect correlation between the two TSNAs resulted in a combined non-compliance rate of 56e66% (Fig. 3B ) for these two toxicants. The non-TSNA toxicant limits, being based on 125% of the market median, produced fewer non-compliant products than the two TSNAs. The individual non-compliance rates for the non-TSNA toxicants ranged from 4% (benzene in Romania) to 24% (1,3-butadiene in Brazil), with a combined non-compliance rate of 34e45% for these 7 toxicants (Fig. 3B) .
Regarding the number of toxicants for which each individual product was non-complaint (Fig. 3C) , it was most common for products to be non-compliant for 0, 1 or 2 toxicants (20%e30% of products for each), followed by 3 toxicants (~10%), and then 4e9 toxicants (<5% for each). The two TSNAs accounted for most products with 1 or 2 toxicant non-compliances, whereas the third most common non-compliant toxicant varied by market: 1,3-butadiene in Brazil and Australia; formaldehyde in Romania and Germany (Fig. 3A) .
Model 2 -TobReg fixed toxicant limits
The application of limits based on 'International brands' or 'Canadian brands', set by TobReg under model 2 for use in the absence of market specific information (WHO, 2008) , resulted in an increase in overall numbers of non-compliant products, as compared with model 1's calculated market-specific limits, for most market comparisons (Table 4 ). This increase was often substantialdfor example, 100% of products in Brazil were noncompliant against both of TobReg's fixed limits (Fig. 4A and B) . Application of the International brands limits to the predominantly US-blended German market (Table 4 , Fig. 4A ), increased the percentage of non-compliant products from 80% to 89%. Similarly, application of the Canadian brands limits to the predominantly flue-cured Australian market resulted in an increase in noncompliant products from 72% to 80%. Only the Romanian market (mixed blend; high incidence of charcoal in the filter) showed a reduction in non-compliant products from 78% to 71% when the International brands limits were compared with the marketspecific limits of model 1.
Comparing product non-compliance rates for NNN and NNK when using the two sets of fixed limits compared to the market specific limits of model 1 (Figs. 3A and 4) , showed that use of the international brands limits resulted in a marked decrease in noncompliance levels against the TSNA limits for 3 of the markets surveyed in this study, whilst for the Brazilian market noncompliance rates were similar (~60%). Applying the Canadian brands fixed limits for NNN and NNK increased non-compliance rates for 3 of the markets substantially (>90%), whereas for the Australian market there was a small decrease in non-compliance rates, from 56 to 50%.
Product non-compliance rates for non-TSNA toxicants when using TobReg fixed limits showed a marked increase to 66%e99% non-compliance, compared to~40% non-compliance when using the market-specific limits of model 1 (Figs. 3B and 4) . Formaldehyde limits produced the greatest number of non-compliances under the 'International brands' set of limits (59e88% noncompliance), but a negligible level of non-compliance under the 'Canadian brands' limits (1e2% non-compliance). Conversely, acetaldehyde emissions produced high levels of non-compliance under the 'Canadian brands' limits (45%e88%), but lower levels of non-compliance under the 'International brands' limits (1%e36%). Formaldehyde was the main driver of non-compliance when applying the 'International brands' limits in each of the four markets whilst NNN, followed by NNK (except for the Australian market products), acetaldehyde, benzene (except for the Romanian market products) and 1,3-butadiene were the main drivers when applying the 'Canadian brands' limits. The Brazilian market in particular was negatively affected by the use of the fixed limits with the highest levels of non-compliance for each toxicant individually, apart from 1,3-butadiene, and 100% non-compliance when applying all 9 limits simultaneously under either set of limits.
Model 3 limits
The level of product non-compliances obtained when applying the model 3 limits to each of the appropriate markets are summarized in Table 4 . The total level of non-compliances varied significantly by market, ranging from 68% in Australia to 99% in Germany. The impact on the Australian and Romanian markets were comparable to that found with the market-specific limit model. However, the model 3 limits produced significantly higher levels of non-compliances for the Brazilian (86%) and German markets (99%).
The levels of non-compliances against the model 3 limits were Fig. 3 . Proportion of non-compliant products by market using market-specific ceilings (model 1) (A) Separate application to toxicants (B) Simultaneous application of toxicant limits (C) Number of non-compliant toxicants per product. driven strongly by NNN, and to a lesser degree, by NNK, Fig. 5 . The other seven toxicants resulted in few non-compliances, other than with formaldehyde in Romania (35% non-compliances) and Germany (14%), and with B[a]P in Romania (17%) and Brazil (15%).
Discussion
The principal goal of TobReg's proposed strategy is to reduce the emissions of nine selected mainstream smoke toxicants in commercial cigarettes by excluding products with the highest smokingmachine measured levels of these toxicants. TobReg's proposals are based on a complex trade-off of considerations that they believe will result in substantial lowering of toxicant emissions, while not resulting in the elimination of most of the brands sold on a market. This study represents the first full evaluation of this global proposal for tobacco product regulation, and has explored the impact of the proposed regulations on real-world, whole-market data. A number of important learnings have emerged from this analysis.
Toxicant ceilings arising from TobReg models
Comparison of model 1 and model 2 limits
The suitability of TobReg proposed fixed limits for global deployment can be assessed by comparison with the individual market limits calculated in this work, Table 2 . Very few of the individual limits from the four markets examined in the current work gave a set of limits that matched the TobReg proposals. Comparing the Australian market limits to the TobReg limits calculated from the Canadian brands showed that while NNN and B[a]P limits were in exact agreement, CO and acrolein limits differed by 8e10%, benzene limits by 14%, acetaldehyde, formaldehyde and 1,3-butadiene limits differed by 20e30% and NNK limits differed by 55%.
Similarly, comparing the TobReg limits calculated from the International Brands dataset with the limits obtained in this study from the German, Romanian and Brazilian datasets also showed significant disagreements. CO limits differed by 3e12%, acetaldehyde limits by 4e16%, 1,3-butadiene limits by 3e19%, acrolein limits by 5e28%, NNK limits by 8e36%, B[a]P limits by 18e27%, benzene limits by 10e44%, NNN limits by 21e37% and formaldehyde limits by 30e57%.
Given the sensitivity of compliance/non-compliance to small changes in limits or emission ratios around the median and 125% median values (Section 4.3) these observations clearly demonstrate that the TobReg proposed fixed limits are inappropriate for use in these four markets, and most likely on a global basis.
In understanding why the TobReg proposed fixed limits do not reflect actual market limits, it should be noted that TobReg did not use full-market data to calculate either set of limits: the 2004 Canadian emissions dataset contained measured toxicant emissions data for only a subset of the products listed (60 out of 249 brands sold in Canada in 2004), on top of which data from US and French blend cigarettes were removed (products where NNN levels > 100 ng/mg of nicotine), leaving a final set of 48 products. For the 'International brands', the 49 products reported by Counts et al. (2005) were from a single manufacturer, with few charcoal filtered or reduced circumference products. Neither dataset reflects the breadth of products available in any one market, let alone worldwide.
The substantial differences in non-compliance rates when using either of the TobReg fixed limits, together with the lack of fit with limits calculated from actual market data, highlights how important it would be to have accurate, contemporary, market-specific data if the proposed approach were to be enacted, particularly given the potentially high rates of product non-compliance observed in the present study.
Model 3 limits
With model 3 the toxicant limits (Table 3) are defined by the emissions of one product for each toxicant in each market, and therefore interpretation of these observations is likely to be challenging, as the product defining the market limit may be unrepresentative of the overall market. For example, Germany, a USblended market, has the lowest TSNA limits of the four markets, despite having one of the widest distributions of TSNA emissions of the markets examined in this survey (Supplementary Fig. 1 ). In contrast, the Australian formaldehyde limit is the highest of the four markets, which is a representative reflection of the predominantly flue-cured nature of the tobacco products sold on this market. Another example of the potential for unrepresentative products defining market limits under model 3 is provided by the Brazil market. Brazil provided five of the lowest model 3 limits (defined by a single product for each toxicant) in the overall dataset. This is in direct contrast to the findings from application of model 1 (defined by all products on the market), where Brazil had seven of the highest limits. Clearly, the method for calculation of toxicant limits has a profound impact on the standards that products would have to meet if these models were enacted.
Product compliance with toxicant ceilings
Model 1 -individual market limits
Our survey of four markets that differ in tobacco blend style, cigarette design and toxicant profiles has shown that the impact of this proposed regulatory strategy would be consistently severe: 72%e80% of the products analysed in each market were noncompliant with the market-specific limits (Fig. 3B ). There were two main drivers of the high non-compliance levels: the primary driver being use of median market yields as the ceiling for NNN and NNK emissions which in itself resulted in 56e66% failures; and a secondary driver being the simultaneous application of 9 separate toxicant ceilings. The end result, where most products in a market cannot comply with proposed ceilings, clearly does not meet the stated intention of TobReg of providing a regulatory framework that does not cause elimination of most brands in their current form from the market.
Model 2 -fixed limits
Application of the two sets of 'fixed' TobReg proposed limits was associated, in almost all cases, with substantially higher noncompliance rates than found with market-specific limits (model 1). In some cases 100% non-compliance was observed. The extent of product failures with the International Brand limits was 70e100%, and 80e100% with the Canadian brands limits (Fig. 4A and B) .
On application of the 'International brands' limits the increase in non-compliances was driven by the non-TSNA toxicants, particularly formaldehyde, rather than the two TSNAs. Brands failing the 'International' formaldehyde limits reached as high as 88%, and up to 83% failed the benzene limits; conversely in most cases failures against TSNAs were <30%.
In contrast, for the 'Canadian brands limits' the increase in noncompliance rates arose from a number of toxicants and varied by market: there were large increases in NNN and NNK noncompliances for Brazil, Romania and Germany (NNN only) and in non-compliances with acetaldehyde and 1,3-butadiene, but the non-compliance rate for formaldehyde was negligible.
TobReg's impact assessment estimated 40e41% product failures, driven by the 7 toxicants other than NNN and NNK, an estimation based upon the belief that TSNA emissions could be lowered by cigarette manufacturers without difficulty. Our analysis clearly demonstrates much higher levels of non-compliances when actual products are examined, reaching 100% in some cases. Even the impact of the seven limits for toxicants other than the TSNAs was more severe than estimated by TobReg, with 66e99% failures against the International Brands limits, and 66e90% noncompliances with the Canadian brands limits. Therefore, use of the proposed fixed limits does not meet the TobReg intention of toxicant reduction without severe disruption to a market.
Model 3 limits
Application of the model 3 limits (3 Â market minimum levels) also caused greater levels of non-compliance than the TobReg model 1 limits (based on market median) in 2 of the 4 markets surveyed in this work (Table 4) . This was predominately driven by the limits for TSNAs and NNN in particular; with the other seven toxicants having relatively little impact on compliance (Fig. 5) .
The model 3 limits were described as generous (WHO, 2015) , however when their impact is examined on typical cigarette markets, their impact has been shown to be severe, with 99% noncompliances in Germany.
Limits calculated under model 3 are highly susceptible to low yield, atypical products. Germany was by far the largest market surveyed and had an overall TSNA distribution comparable to Brazil and Romania, and much higher than Australia ( Supplementary  Fig. 1 ). Nevertheless, due to the low TSNA emissions of one product on the German market, the NNN and NNK limits for the German market were the lowest of the four markets examined in this work, which resulted in 99% non-compliances with the products sold in Germany.
Two factors may present difficulties for the model 3 approach. First, low level quantification of smoke toxicant emissions can be particularly sensitive to analytical imprecision. At low levels, such as at the limit of quantification, analytical errors can have a substantial impact on the measured value. Second, no guidance was provided (WHO, 2015) on the most appropriate procedure under model 3 when the lowest emission value on a market are below the limits of quantification, and this represents a serious shortcoming of the proposals.
Toxicant yields as a ratio to nicotine
With the first two TobReg models, the recommendation was to express toxicant emission data as a ratio to the measured smoke yield of nicotine in order that the machine measured values are not misleadingly judged to represent a measure of human exposure and therefore risk (WHO, 2008) . In contrast, the later model 3 proposals, published in WHO Technical Report 989, proposed use of per-cigarette yields rather than values calculated as a ratio to nicotine emissions. To understand the importance of these differences in model approaches, we therefore examined the data obtained in this study to assess the impact of using nicotine ratios on product compliance.
Analysis of the data showed that setting an emission limit for a toxicant on the basis of its yield ratio to nicotine resulted in some products with high absolute toxicant emissions being compliant with toxicant/nicotine limits when they had a relatively high nicotine yield. Fig. 6 provides an example demonstrating the relationship between nicotine and NNN yields, and NNN-to-nicotine yields for the German market products when compliance is categorised using the model 1 approach, and the calculated market median for NNN-to-nicotine emissions of 72 ng/mg (Fig. 6A) . Fig. 6B shows that some compliant products have higher NNN emissions than non-compliant products, which seems counterintuitive. For example, 80 out of the 169 'non-compliant' products (in terms of NNN-to-nicotine yields) have absolute NNN yields that are lower than that of the 'compliant' product with the highest NNN yield (171 ng/cig). Conversely 92 out of 169 'compliant' products (in terms of NNN-to-nicotine yields) have absolute NNN yields that are higher than that of the 'non-compliant' product with the lowest NNN yield (98 ng/cig). This is a point of major concern as Clinical studies have demonstrated that products with higher NNN emissions lead to greater NNN exposure amongst smokers (as measured by biomarkers of exposure) than products with lower NNN emissions (Shepperd et al., 2013) , and similarly for NNK (Czoli and Hammond, 2015) . Fig. 6C shows that nicotine emission levels make a significant contribution to whether products are compliant to the NNN/nicotine limit, with non-compliant products associated with lower level nicotine emissions, however this contribution is much lower than the magnitude and differences in NNN emissions. Fig. 7 shows similar plots to Fig. 6B for the remaining 8 toxicants for the German market products, i.e. toxicant yields categorised by compliance to the model 1 market specific calculated toxicant-tonicotine ceiling. The analysis shows that the volatile species are even more prone to this effect, with significant overlap in percigarette emissions between compliant and non-compliant products. A similar full set of plots for the Brazilian, Romanian and Australian market survey data are included in Supplementary  Figs. 3-5 .
These observations highlight an important concern over the TobReg models based on use of emission values as a ratio to nicotine levels, as the practical consequences are contrary to TobReg's stated intention of excluding products with the highest toxicant emissions, as well as having implications for human exposure.
Impact of measurement error on TobReg proposals
All analytical measurements are associated with uncertainty, imprecision or inaccuracy, arising from a combination of analytical error and variation in the manufactured product. Measurement of mainstream smoke toxicant emissions in particular are associated with a significant amount of variation (Hyodo et al., 2006; Morton and Laffoon 2008; Gaworski et al., 2011; Intorp et al., 2009; Teillet et al., 2013; Purkis and Intorp, 2014; Eldridge et al., 2015) . By definition, the median values that are pivotal to the TobReg model lie in the middle of the data series, which for normal or near normal distributions (such as that seen for cigarette smoke toxicant data, see Supplementary Figs. 1 and 2) is the most densely populated portion of the data distribution. This region is most susceptible to these errors (Fig. 8) , with consequential uncertainty over the relative positions of individual products in a ranked population. We therefore investigated whether measurement error significantly influences product compliance with TobReg proposed ceilings.
To assess the impact of measurement error on product compliance, the potential error in smoke toxicant ratio emission measurements, calculated as ±2 times the coefficient of variation (2CV), has been determined when using this single ISO 17025 accredited laboratory in terms of both the repeatability of the measurement method, based on a reference cigarette, and the variation observed when analysing repeatedly manufactured commercial cigarette products . Applying the potential measurement error to the NNK-to-nicotine emissions for the German market products demonstrates the practical consequences of these sources of variability (Fig. 8) : a hypothetical product with a "true" NNK/nicotine value at the measured median limit of 46 ng/mg has an uncertainty of measurement that means that measured values between 31 and 62 ng/mg of actual NNK/nicotine can be obtained from the measurement laboratory. Hence the compliance or noncompliance of this hypothetical product would be a question of chance. This range of possible measurement values is similar to the interquartile range of all NNK-to-nicotine measurements in the German market (34e63 ng NNK/mg nicotine, Table 1 ). Therefore, to guarantee compliance with a median limit, and minimise the impact of measurement uncertainty, a true value around the lower quartile value would be the necessary performance target for a brand. In this study only 20%, or 67 out of 339, of the German products measured could be reliably determined as compliant for NNK/Nicotine due to the impact of measurement uncertainty, and in the same way only 26%, or 89 out of 339 products, could be reliably determined as non-compliant.
By contrast, the effect of likely measurement error on toxicant emission ratios when limits are based on 125% of the median was, in general, less pronounced in terms of the number of products affected. The impact of measurement error will depend both on where the 125% of the median limit lies within the distribution of emission data and on the magnitude of the potential error. Using the typical measurement error reported by Eldridge et al. (2015) , the best-and worst-case scenarios from this study are shown in Fig. 9 : the best case scenario being CO/Nicotine in Romania (Fig. 9A) , where the potential measurement error affects~20 out of the 138 products, and the worst case 1,3-butadiene/nicotine in Romania (Fig. 9B) , where the potential measurement error encompasses all 138 products measured. The uncertainty in 1,3-butadiene/nicotine product compliance arises due to substantial longitudinal analytical variation previously observed with 1,3-butadiene analysis; over a 10-month period 2CV values of 46% were reported Cumulatively, this more stringent performance standard introduced by real-world measurement uncertainty would reduce the number of products that could be guaranteed to be compliant to around zero when 9 simultaneous limits are considered, (see Supplementary Tables 3 and 4 for the impact on non-compliance rates, including measurement error, for each toxicant in each of the four markets).
It might be considered that increasing the product sampling frequency may reduce the impact of measurement uncertainty. However, the effectiveness of this strategy is contingent on measurement variability arising solely or predominately from product rather than analytical sources. In the case where analytical errors are a major contribution to the overall measurement variability then further measurements cannot be guaranteed to reduce measurement error.
All the present data were acquired in a single laboratory and for one-point-in-time samples, and therefore does not include product variability nor the variability observed between results arising from different laboratories. Significant levels of between laboratory variation have been previously reported d up to 18% CV between 3 laboratories (Hyodo et al., 2006) and up to 100% CV (70% CV excluding 1,3-butadiene) between 15 laboratories (Intorp et al., 2009) , for the 9 toxicants from this study. This suggests that meeting toxicant ratio emission limits through measurements carried out at a number of different laboratories might be even more strongly influenced by measurement uncertainty than measurements in a single laboratory.
Effective product regulation is fundamentally dependent on accurate and precise determination of smoke toxicants, as well as the availability of technically feasible technologies for their reduction. Current analytical methods are capable of producing precise single-point-in-time measurements; however, a lack of standardised methods and certified reference materials means that accuracy is compromised, owing to substantial variation over time, within and particularly between laboratories (Morton and Laffoon 2008; Intorp et al., 2009; Oldham et al., 2014 . Our study demonstrates that for the majority of products on-sale on a market, compliance with TobReg proposals would be strongly influenced by random measurement variability; management of product toxicant emissions under these circumstances would be a highly challenging activity.
Multiple toxicant limits
TobReg conducted an assessment of correlations between different toxicant emissions from products in their database (WHO, 2008) , and found evidence for both positive correlations between toxicants, such as between NNN and NNK, as well as negative correlations such as those between formaldehyde and TSNAs or between benzo[a]pyrene and carbonyls. To further understand the impact of the simultaneous application of multiple limits on numbers of product non-compliances we examined the extent to which the nine toxicants were correlated. This exercise is of value because the current study generated a significantly larger database than that used by TobReg. To achieve this, Pearson's correlation coefficients (r) were determined among the toxicant emission yields for each market (Table 5) , after excluding the four atypical products discussed in Section 3.2.
Toxicant emissions that were predominantly driven by precursors in the tobacco filler blend (NNN, NNK, formaldehyde and B [a]P) showed the poorest levels of correlation both amongst themselves and against the volatile and gaseous toxicant yields. B [a]P correlations varied widely across toxicants and also against the same toxicant across the four markets. Formaldehyde correlations were positive and weak across the majority of toxicant comparisons but negative against both TSNAs. Even yields of the chemically similar NNN and NNK showed varying degrees of correlation, ranging from moderate (r ¼ 0.475), for Romanian market products, to very strong (r ¼ 0.864) for Australian market products. This analysis demonstrates that toxicant yields are inter-related to varying degrees, with evidence of both positive (e.g. between CO and volatile toxicants) and negative (e.g. between TSNAs and formaldehyde, or between TSNAs and 1,3-butadiene) correlations (Table 5) .
The generally weak and inconsistent correlations are a concern for compliance with the TobReg proposals, as it results in a greater number of non-compliances when applying limits to each of the nine toxicants simultaneously: for example, the 50% noncompliance rate observed for an individual TSNA rose to approximately 60% for both TSNAs (Fig. 3B) . Furthermore, as these relationships are not totally consistent across different markets, effective management of toxicant yields by cigarette manufacturers across multiple markets under this regulatory proposal would be a highly complex affair. In particular, the negative correlations suggest that reducing yields of nitrosamines could lead to an increase in yields of formaldehyde and 1,3-butadiene to some degree, as seen when comparing the Australian market data to the other markets examined in this study.
Logistical considerations
The present study highlighted the logistical challenges in obtaining samples of all currently available commercial cigarette products for a given market. Commercial cigarettes are "fastmoving consumer goods" and there is continuing evolution in the identity of products in a market place, many of which will have low market share or use by smokers. As a result, in our experience, sourcing all products on-sale in a market is highly challenging, and we were not able to do so in any of the four markets studied. Overall, 80%e97% of the 'snapshot list' of commercial products were obtained for the markets in this study. Even in Brazil, where the identity of all products is clear, due to a paid product registration process with the regulatory authority (ANVISA), it was not possible to sample all products. Although it was straightforward to generate a list of products, it took many weeks to source all of the available products in some markets, and in that time a number of products were removed from the market. In addition, for some competition products with a small sales volume, it was not possible to obtain sufficient cigarettes (>400) on the open market for analysis. Because all products contribute equally to the setting of TobReg proposed limits, limits created in this way may reflect a point-in-time picture of a market, rather than a long term stable view. The extent to which market dynamics may vary in overall toxicant profiles over time is unclear and requires further examination.
Given the logistical challenges of sampling all products from a market, the most efficient method of collecting all products would be to require the cigarette manufacturers to analyse or provide samples for analysis. However, TobReg have expressed concerns over manufacturers providing sample products for analysis and instead recommend obtaining product directly from the market or through unannounced collection during manufacture or distribution. This latter route may be the only practical approach for sampling a complete market, but also relies upon frequent or continuous production or availability of a product. With small sales volume products this may not be the case.
Practicality of reducing TSNA toxicant emissions
TobReg's basis for using the market median as a limit for TSNAs are: the observation that a comparatively wide range of NNN and NNK emissions are observed for cigarette products around the world; the view that one of the two main styles of tobacco (fluecured Virginia or "bright" tobacco) is naturally lower in TSNA levels than the other (air-cured Burley); and reports that nitrosamine contents of US and Canadian flue-cured tobaccos were declining due to changes in flue-curing approaches in these countries (IARC, 2004; Gray and Boyle, 2004) . TobReg therefore regarded reducing TSNA levels via the proposed limits as straightforward to achieve by changing the tobacco blend for those with lower toxicant potential.
However, use of the median as a toxicant ratio emission limit is intrinsically problematic: no matter how high or low, or widespread the data or its distribution, half of the products on a market will fail to meet a median limit by definition. Therefore, for markets with the lowest toxicant/nicotine distribution, the practical mechanism for compliance with limits is unclear. For example, with Australian products where NNN/nicotine levels were the lowest of the countries in the current survey, substitution by brands from other markets is unlikely to be a practical solution, and compliance with limits may rely upon the availability of a limited pool of low toxicant precursor tobaccos.
The negative correlation between TSNA/nicotine and formaldehyde/nicotine suggests that the simple framework of reducing each of the 9 toxicant/nicotine emissions from cigarettes may be more complex than previously considered, with the potential for unintended impact on emissions of other toxicants. The scope of this was examined by comparing the distribution of toxicant/ nicotine emissions across the four markets ( Supplementary Fig. 2 ). With NNN/nicotine, the data shows significant commonality in values, other than the Australian products, which showed a lower distribution (but still with significant overlap) to the other three markets. In contrast, with formaldehyde/nicotine Australian products (together with Brazilian products) showed wider distribution of values than the other two markets. Consequently, reductions in NNN/nicotine might be achievable in the Romanian and German markets by changing to an Australian product profile but at the cost of increased formaldehyde/nicotine, and consequent potential for failure against this limit. The consumer acceptability of these changes in product styles is also unclear.
TobReg expressed the view that compliance to the levels mandated for NNN and NNK will be readily achievable through established blending and curing practices (WHO, 2008) ; however, the practical mechanisms by which this could be achieved, and their feasibility on national or global scales is unknown. As noted by Gray and Boyle (2004) "the international tobacco trade is complicated, often based on an auction system, and the introduction of nitrosamine assays on unmanufactured tobacco would be difficult. Certainly regulations could enforce a prohibition on manufacture and sale of high nitrosamine tobacco, but both import and export regulation would be required by many countries, and would need to be applied to tobacco as well as tobacco products. While all this is possible in theory, in practice it is likely that the developed countries will protect themselves best and others probably not at all".
Conclusion
The present study has provided the first full assessment of the practicalities and impact of three WHO TobReg regulatory proposals for the emissions of nine toxicants in mainstream cigarette smoke.
Our study sampled products according to TobReg's proposals, and we measured the emissions of all available products from four countries with different product styles. The TobReg process of sampling and analysing all products on a market was found to be logistically challenging, and our experience suggests it may not be possible to achieve in practise unless products are sampled from manufacturing sites. When the TobReg model of market-specific limits are applied, 70%e80% of products sold in each of the four countries (Australia, Brazil, Germany and Romania) were found to be non-compliant with the toxicant limits, and thus would require substantial redesign to continue to be sold in the subsequent regulated market. Application of the second TobReg model of fixed limits (both 'International brands' or 'Canadian brands' set limits) resulted in, often substantial, increases in non-compliance rates both at an individual toxicant level and when applying multiple toxicant limits simultaneously. In some cases, all products on a market failed to meet the TobReg-provided limits. A third, recently proposed model, of setting limits based on three-times the lowest emission levels of products on a market, shows similar challenging results, with 68e99% non-compliances. This latter model is particularly sensitive to the impact of atypical products on a market, and may be challenged by analytical errors and emission levels too low to be quantified.
Use of the market median to set toxicant limits is technically challenging to comply with: first, half of the products on the market are automatically non-compliant; and second, when the likely measurement error is taken into account, compliance with the proposed limits is highly influenced by product and analytical variability for a large proportion of products.
Simultaneous application of all nine toxicant limits also contributes substantially to the high levels of non-compliance owing to the lack of close positive correlation between many toxicant emission levels. Evidence of negative correlation (between TSNAs and formaldehyde, or between 1,3-butadiene and NNN, NNK or formaldehyde) suggests that reducing yields of some toxicants would lead to an increase in yields of other toxicants. Very different limits for each toxicant were calculated across the four markets, with limits for TSNAs ranging more than threefold. Furthermore, regulating toxicant emission levels as a ratio to nicotine yields increases the complexity of the regulation and allows some products with relatively high toxicant emissions to register as compliant if their nicotine yields are also high.
A fundamental finding of our study is that each of the three TobReg proposed toxicant limit models go far beyond TobReg's aims of reducing toxicant levels in cigarette smoke whilst not eliminating the majority of cigarette brands in their current form from a market.
